Investor Update

Basel, 24 August 2007

Genentech announces resubmission of supplemental Biologics License Application for Avastin in combination with paclitaxel for first-line metastatic breast cancer

Dear Investor,
Please find attached a Genentech news release announcing that the company resubmitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin (bevacizumab), in combination with paclitaxel chemotherapy, for patients who have not received chemotherapy for their locally recurrent or metastatic breast cancer.  The resubmission, based on the pivotal Phase III trial (E2100), marks the beginning of a six-month review period by the FDA.